<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Low fibrinolytic activity may increase the risk of <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Plasminogen activator inhibitor-1 (PAI-1) is an inhibitor of the fibrinolytic system </plain></SENT>
<SENT sid="2" pm="."><plain>We examined the PAI-1 levels in patients with <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Plasma levels of PAI-1 were measured using enzyme-linked immunosorbent assay (ELISA) in 55 consecutive patients (age 60.2 +/- 11.4, 40 males and 15 females) with <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>The PAI-1 assessments as well as neurological examinations using validated <z:hpo ids='HP_0001297'>stroke</z:hpo> scales were conducted at admission and 1 week, 1 month, and 3 months after <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Sex- and age-matched controls (+/- 4 years) underwent plasma PAI-1 measurement once </plain></SENT>
<SENT sid="6" pm="."><plain>Etiology of the <z:hpo ids='HP_0001297'>stroke</z:hpo> was classified using the Trial of Org 10172 in <z:hpo ids='HP_0011009'>Acute</z:hpo> <z:hpo ids='HP_0001297'>Stroke</z:hpo> Treatment (TOAST) criteria </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> pertinent <z:hpo ids='HP_0001297'>stroke</z:hpo> risk factors were recorded </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients were contacted 3 years after <z:hpo ids='HP_0001297'>stroke</z:hpo> for recurrent vascular <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombotic disease</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>The plasma PAI-1 levels were 17.2 +/- 7.8 IU at admission, 11.2 +/- 9.2 IU at 1 week, 14.4 +/- 7.9 IU at 1 month, and 17.8 +/- 7.8 IU at 3 months among patients and 11.8 +/- 9.5 IU among controls (p values are &lt; .002, .7, .12, and &lt; .0005, respectively) </plain></SENT>
<SENT sid="10" pm="."><plain>As a rule, the neurological scores did not show a correlation to the PAI-1 levels </plain></SENT>
<SENT sid="11" pm="."><plain>Presence of <z:mp ids='MP_0002055'>diabetes</z:mp>, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, <z:hpo ids='HP_0001513'>obesity</z:hpo>, smoking, <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> treatment, and <z:hpo ids='HP_0010535'>sleep apnea</z:hpo> did not affect the PAI-1 levels at any time point </plain></SENT>
<SENT sid="12" pm="."><plain>Females had slightly higher PAI-1 levels </plain></SENT>
<SENT sid="13" pm="."><plain>Age was a strong determinant for PAI-1 levels being higher in younger patients at every sampling time point (p values .02, .02, .02, and .03 respectively) </plain></SENT>
<SENT sid="14" pm="."><plain>The etiology of the <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> did not have an impact on PAI-1 levels </plain></SENT>
<SENT sid="15" pm="."><plain>In 16 patients <z:hpo ids='HP_0004419'>recurrent thrombosis</z:hpo> had occurred </plain></SENT>
<SENT sid="16" pm="."><plain>The high PAI-1 levels at admittance may reflect either an <z:hpo ids='HP_0011009'>acute</z:hpo> phase response or a <z:hpo ids='HP_0011010'>chronic</z:hpo> state </plain></SENT>
<SENT sid="17" pm="."><plain>Normalized levels at 1 week and 1 month may be due to hospital diet, antithrombotic medication, <z:hpo ids='HP_0001824'>weight loss</z:hpo>, active physical therapy, and better care for <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="18" pm="."><plain>PAI-1 levels at 3 months after <z:hpo ids='HP_0001297'>stroke</z:hpo> did not predict <z:hpo ids='HP_0004419'>recurrent thrombosis</z:hpo> </plain></SENT>
</text></document>